CN119173533A - TGF-β抗体 - Google Patents

TGF-β抗体 Download PDF

Info

Publication number
CN119173533A
CN119173533A CN202380038825.XA CN202380038825A CN119173533A CN 119173533 A CN119173533 A CN 119173533A CN 202380038825 A CN202380038825 A CN 202380038825A CN 119173533 A CN119173533 A CN 119173533A
Authority
CN
China
Prior art keywords
seq
antibody
tgf
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038825.XA
Other languages
English (en)
Chinese (zh)
Inventor
L·马里恩
G·德伯克
S·卢卡斯
F·安贝尔
S·P·范德沃宁
S·利纳特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Publication of CN119173533A publication Critical patent/CN119173533A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380038825.XA 2022-03-09 2023-03-09 TGF-β抗体 Pending CN119173533A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2203269.2A GB202203269D0 (en) 2022-03-09 2022-03-09 TGF-Beta antibodies
GB2203269.2 2022-03-09
PCT/EP2023/056082 WO2023170241A1 (en) 2022-03-09 2023-03-09 TGF-β ANTIBODIES

Publications (1)

Publication Number Publication Date
CN119173533A true CN119173533A (zh) 2024-12-20

Family

ID=81175458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038825.XA Pending CN119173533A (zh) 2022-03-09 2023-03-09 TGF-β抗体

Country Status (9)

Country Link
US (1) US20250188161A1 (https=)
EP (1) EP4490186A1 (https=)
JP (1) JP2025508073A (https=)
CN (1) CN119173533A (https=)
AU (1) AU2023229972A1 (https=)
CA (1) CA3245104A1 (https=)
GB (1) GB202203269D0 (https=)
IL (1) IL315033A (https=)
WO (2) WO2023170241A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
ES2860952T3 (es) 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
AU2018387829B2 (en) 2017-12-22 2024-12-19 Argenx Bvba Bispecific antigen binding construct

Also Published As

Publication number Publication date
EP4490186A1 (en) 2025-01-15
WO2023170242A1 (en) 2023-09-14
JP2025508073A (ja) 2025-03-21
IL315033A (en) 2024-10-01
WO2023170241A1 (en) 2023-09-14
GB202203269D0 (en) 2022-04-20
AU2023229972A1 (en) 2024-09-12
CA3245104A1 (en) 2023-09-14
US20250188161A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
US11242404B2 (en) Antibodies against signal-regulatory protein alpha and methods of use
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN114174338A (zh) 与gprc5d结合的抗体
JP2020528768A (ja) 抗ｔｉｇｉｔ抗体
WO2019152715A1 (en) Anti-ms4a4a antibodies and methods of use thereof
JP2023528350A (ja) Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
US11447544B2 (en) Anti-IL-22R antibodies
TW202120547A (zh) 抗ms4a4a抗體及其使用方法
JP2023548034A (ja) デルタ様リガンド３（ｄｌｌ３）抗原結合ドメインを含むタンパク質及びその使用
KR20210057752A (ko) 항-cd38 항체, 이의 항원 결합 단편, 및 제약 용도
KR20260051068A (ko) Enpp3 및 cd3 결합제 및 이의 사용 방법
KR20250096769A (ko) 글리피칸-3에 대한 이중특이성 항체 및 이의 용도
US20250188161A1 (en) TGF-ß ANTIBODIES
RU2800779C2 (ru) Биспецифичные антигенсвязывающие молекулы и способы их применения
WO2025067469A1 (zh) Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
CN121969650A (zh) Ror1抗体的糖工程化形式和使用方法
AU2024322975A1 (en) Anti-ox40l antibody and use thereof
CN122003438A (zh) Enpp3和cd3结合剂及其使用方法
CN115698078A (zh) 人源化抗人cd89抗体及其用途
HK40061355A (en) Antibodies binding to gprc5d
BR112015022593B1 (pt) Proteína de ligação de antígeno, anticorpo humanizado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira microbiana e métodos de produção de uma proteína de ligação de antígeno e de um anticorpo humanizado, composição farmacêutica
GB2543729A (en) Antibodies to IL-24

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination